SCHEMBL2550385

SCHEMBL2550385

C#CCC[C@H](N)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL869479 1.00
SCHEMBL2548392 1.00
Hydrochloric Acid SCHEMBL23036797 0.98 GRIK1 (0.48)
SCHEMBL600685 0.86 GSR (0.54)
SCHEMBL600686 0.86 GSR (0.54)
SCHEMBL2548396 0.86 GSR (0.54)
Racemethionine SCHEMBL23675421 0.85 BHMT (0.45)
SCHEMBL2546202 0.85 GSR (0.57)
SCHEMBL2548695 0.85 GSR (0.57)
SCHEMBL2546200 0.85 GSR (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3297670-B1 LINKER UNITS WITH TARGETING AND EFFECTOR ELEMENTS IMMUNWORK INC (TW) 2025-07-02 EP claimed
US-20250115943-A1 SYSTEM AND METHOD FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING FUNDAMENTAL SOLUTIONS CORP (US) 2025-04-10 US claimed
WO-2025076510-A1 SYSTEM AND METHOD FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING FUNDAMENTAL SOLUTIONS CORPORATION (US) 2025-04-10 WO claimed
EP-3344659-B1 MOLECULAR CONSTRUCTS FOR PREVENTING THE FORMATION OF BLOOD CLOT AND/OR TREATING THROMBOSIS IMMUNWORK INC (TW) 2025-03-26 EP claimed
US-20250074943-A1 DLL3 BINDING PEPTIDES AND USES THEREOF AMGEN INC. 2025-03-06 US claimed
WO-2024238632-A2 ASYMMETRIC CIRCULAR TANDEM REPEAT PROTEINS Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute (US) 2024-11-21 WO claimed
EP-4453001-A2 DLL3 BINDING PEPTIDES AND USES THEREOF AMGEN INC. (US) 2024-10-30 EP claimed
EP-4416300-A1 ANTIBIOTIC SUSCEPTIBILITY TEST Fundamental Solutions Corporation (US) 2024-08-21 EP claimed
WO-2023122436-A2 DLL3 BINDING PEPTIDES AND USES THEREOF AMGEN INC. (US) 2023-06-29 WO claimed
WO-2023064472-A1 ANTIBIOTIC SUSCEPTIBILITY TEST FUNDAMENTAL SOLUTIONS CORPORATION (US) 2023-04-20 WO claimed
US-20230020297-A1 UOX-ALBUMIN CONJUGATE WITH CERTAIN NUMBERS OF ALBUMIN CONJUGATED THERETO, AND MANUFACTURING METHOD THEREOF PROABTECH CO., LTD. (KR) 2023-01-19 US claimed
CN-108271357-B Molecular constructs for treatment of transplant rejection 免疫功坊股份有限公司 2022-06-07 CN claimed
WO-2022104001-A1 EXPANDED PROTEIN LIBRARIES AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2022-05-19 WO claimed
US-11235064-B2 Core constructs and their uses in configuring pharmaceutical molecules Immunwork Inc. (TW) 2022-02-01 US claimed
EP-3057617-B1 NANOPARTICLE-CONTAINING HYDROGELS AGENCY SCIENCE TECH & RES (SG) 2020-04-01 EP claimed
EP-2773696-B1 SELF-ASSEMBLED COMPOSITE ULTRASMALL PEPTIDE-POLYMER HYDROGELS AGENCY SCIENCE TECH & RES (SG) 2017-07-26 EP claimed
US-8637686-B2 Triazole macrocycle systems AILERON THERAPEUTICS, INC. (US) 2014-01-28 US claimed
US-20110263815-A1 TRIAZOLE MACROCYCLE SYSTEMS AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) 2011-10-27 US claimed
CN-122056901-A Pharmaceutical application of harpagoside 金陵药业股份有限公司 2026-05-19 CN disclosed
WO-1998022496-A2 ANTIVIRAL PEPTIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1998-05-28 WO disclosed